Plus-Size Advocates on GLP-1s in 2026: Holding Two Truths at Once
The discourse is loud, and in 2026 it is still loud. On one side, body liberation and Health at Every Size advocates argue that the rush toward GLP-1 medications is a new expression of old anti-fatness. On the other, patients living with the daily realities of larger bodies — joint pain, sleep apnea, diabetes, stigma at every doctor's visit — are finding real relief. Many people exist in both camps. This article is for them.
What Body Liberation Got Right
The body positivity and fat liberation movements made a generation of people safer. They named medical weight bias, pushed back against the assumption that every health problem in a larger body is caused by weight, and argued that human dignity is not conditional on a BMI number. Those contributions are real, and they should not disappear because GLP-1s exist. In 2026, it remains true that fat patients still get worse care on average, that thin does not equal healthy, and that shame is not a clinical intervention.
Why Some Advocates Are Choosing GLP-1s Anyway
And yet, many plus-size advocates have started GLP-1 treatment. The reasons they give in 2026 are usually concrete: their knees hurt, their sleep apnea is severe, their diabetes is progressing, their food noise is exhausting, they want to travel without anxiety, they want to live longer. Choosing a medication is not a rejection of body liberation. It is the exercise of bodily autonomy, which is what the movement was supposed to be about in the first place.
The HAES Tension, Honestly
Health at Every Size as a framework is more nuanced than its critics usually portray. At its core, it argues for weight-neutral care focused on behaviors and wellbeing rather than the scale. A GLP-1 complicates that, because it explicitly produces weight loss. Some HAES practitioners have updated their positions in 2026 to include GLP-1s as a legitimate option for patients who want them. Others have not. The useful question for an individual patient is not which camp wins the argument, but what actually helps them live the life they want.
What the 2026 Evidence Actually Shows
By 2026, GLP-1 medications have accumulated a substantial evidence base. Cardiovascular benefits are well-established. Kidney protection is well-established. Diabetes remission is common. Long-term weight maintenance while on the medication is strong; weight regain after stopping is also well-documented. These are the tradeoffs. The medications work, and for most patients they work long-term, which means staying on them long-term. That is a legitimate choice, not a failure.
Staying Grounded in Community
The loneliest version of the GLP-1 journey is the one where someone feels they've left their community behind. Plus-size advocates who stay connected — to fat liberation spaces, to body-positive friends, to their own values — generally describe a smoother experience. You can take a medication and still refuse to participate in anti-fat culture. You can shrink and still speak up for people who haven't. The work doesn't stop because the scale moved.
Talking With a Clinician You Trust
No article can replace a conversation with a licensed clinician who knows your history, your medications, and your goals. GLP-1 medications in 2026 are powerful and well-studied, but how they fit into your life is a personal question. The right provider will listen, explain the tradeoffs honestly, and help you build a plan that accounts for your whole health picture — not just the number on the scale.